The Synergistic effect of fotemustine and genistein on expressions of p53, EGFR and COX-2 genes in human glioblastoma multiforme cell line
Makaleler > Tam Makale · 2012
Yazarlar: Çığır BİRAY AVCI, Yavuz Dodurga, Nezih Oktar, Sunde YILMAZ SÜSLÜER, Zeynep Özlem Doǧan Şiǧva, Cumhur GÜNDÜZ
Journal of Neurological Sciences, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Scopus, 2012, cilt 29, ss 510-517
Özet
GBM is the most common primary malignant neoplasm of the central nervous system in adults. Fotemustine (FTM) is a cytotoxic alkylating agent and a lipophilic chloroethylnitrosourea derivative. Its mechanism of action consists mainly in inducing DNA strand breaks and cross-linking. Genistein, one of the soy-derived isoflavones, exerts its anticancer properties via several mechanisms, including inhibition of tyrosine phosphorylation, weak estrogenic and anti-estrogenic properties, as an antioxidant, inhibition of topoisomerase II, inhibition of angiogenesis, and induction of cell differentiation in a number of human tumors. We aimed to investigate the anti-proliferative synergistic effect of genistein with fotemustine on human glioblastoma multiforme U87-MG cells. This study was also designed to answer the following question: Do the p53, EGFR, COX-2 genes' expression patterns differ in treatment of these both drugs alone and in combination?